US Food and Drug Administration officials are moving to set biosimilar interchangeability exclusivity policy as some products seeking the designation may be approaching the approval stage.
The first interchangeable biosimilar approved is entitled to one year of exclusivity per the Biologics Price Competition and Innovation Act (BPCIA)
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?